// App-Quantinova.ai

4051 : The JAK Inhibitor Ruxolitinib Elicits Hematologic and Symptomatic Improvement In Patients With Chuvash Polycythemia

Researchers

Presenter

  • Makiko Ban-Hoefen

Principal Investigators

  • Elizabeth K. Engle

  • Eric M. Knoche

  • Charu Kaiwar

  • Karyn Gordon

  • Deborah M. Moore

  • Stephen T. Oh

Medical Centers

  • Pediatrics (Neonatology), University of Rochester Medical Center, Rochester, NY

  • Division of Oncology, Washington University School of Medicine, St. Louis, MO

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Congenital polycythemia

  • Extreme thrombocytosis

  • Myocardial infarction

  • Deep vein thrombosis

  • Polycythaemia vera

  • Pulmonary embolism

  • Thrombocytopenia

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Erythropoietin

  • Ruxolitinib phosphate

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved